VENTURE
73 evidence topics · 13 sources
Objective
Dose finding for weight loss over 13 weeks to inform phase 3
“This study aimed to determine doses of VK2735, a novel glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The VENTURE study was a 13‐week, dose‐ranging study designed to provide preliminary efficacy and safety data for subcutaneous VK2735 as a treatment for obesity to inform phase 3 study design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main objectives of the VENTURE study were to evaluate the safety, tolerability, and weight loss efficacy of VK2735.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered objectives: safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics
Location and study date
Twenty sites in the United States, August 2023 to February 2024
“VENTURE was a phase 2, 13‐week, randomized, double‐blind, placebo‐controlled, parallel‐arm, dose‐finding study conducted in 20 sites in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial was conducted between August 31, 2023, and February 23, 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered study dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2023-08-31” |
| Primary completion (actual) | “2024-02-27” |
| Study completion (actual) | “2024-04-02” |
Topline results announced in February 2024
Study design
Randomized, double-blind, placebo-controlled, parallel-arm, dose-ranging design
“VENTURE was a phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study of weekly subcutaneous VK2735 in adults with obesity or overweight and ≥ 1 weight‐related comorbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total study duration was 23 weeks, comprising a 4‐week screening period, a 13‐week treatment period, and an approximately 6‐week safety follow‐up period (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central randomization and blinding
“All participants were centrally assigned to a randomized study intervention using an Interactive Web Response System (IWRS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Once deemed eligible for enrollment in the study, participants were assigned a sequential randomization number prior to first dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The investigators and study staff were blinded to each participant's assigned study intervention throughout the course of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subcutaneous injections were matched for volume for placebo and active treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered design and masking
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Triple” |
Eligibility criteria
Adults with obesity, or overweight with a weight-related comorbidity, without diabetes
“Eligible participants were over the age of 18 years, with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 and at least one weight‐related comorbid condition (treated or untreated).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight‐related comorbid conditions include hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants with BMI > 50 kg/m2 or with certain medical conditions, including diabetes, were not eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered inclusion criteria
Registered exclusion criteria: diabetes, pancreatitis, calcitonin, and prior incretin or weight-loss drugs
Treatment
Four weekly subcutaneous doses or matched placebo, randomized 1:1:1:1:1
“Participants who met eligibility criteria were randomized to one of four VK2735 weekly subcutaneous injection treatment groups (2.5, 5.0, 10, or 15 mg) or the matched placebo injection group in a 1:1:1:1:1 ratio on day 1 (Figure S1 and Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Placebo injections were matched for volume.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Titration to final dose was conducted as shown in Figure S1 for the active treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fasting was not otherwise required for dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Titration schedule to the final dose in each arm
| Dose arm | Titration schedule |
|---|---|
| VK2735 2.5 mg | “2.5 mg cohort = 2.5 x 13 weeks” |
| VK2735 5 mg | “5 mg cohort = 2.5 mg x 3 wks, 5 mg x 10 wks” |
| VK2735 10 mg | “10 mg cohort = 2.5 mg x 3 wks, 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 4 wks” |
| VK2735 15 mg | “15 mg cohort = 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 3 wks, 15 mg x 4 wks” |
Starting dose of 5.0 mg in the 15 mg arm
Background diet and exercise counseling in all arms
“All participants were encouraged to exercise for approximately 150 min per week and reduce daily intake by 500 kcal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Instructional materials were provided at Week 0 (i.e., randomization), and counseling sessions were conducted at study sites at Week 3, Week 6, and Week 9 (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered intervention description
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary, secondary, and exploratory efficacy endpoints
“The primary endpoint was percent (relative) change from baseline to Week 13 in body weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary efficacy endpoints were observed and change from baseline to Week 13 in body weight and the proportion of participants losing ≥ 5% and 10% of baseline weight at Week 13.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of participants losing ≥ 15% of baseline weight was an exploratory objective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety endpoints
“Safety endpoints included incidence of treatment‐emergent adverse events (TEAEs), treatment‐emergent serious adverse events (TESAEs), and adverse events of special interest.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Changes in vital signs and the proportion of participants with anti‐drug antibodies were also evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory glycemic, cardiometabolic, and anthropometric endpoints
“Key exploratory endpoints included effects of VK2735 on glycemic status, cardiometabolic parameters, and anthropometric parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Categories of glycemic control were defined by fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) as: normoglycemic = FPG < 100 mg/dL and HbA1c < 5.7%, prediabetes = FPG 100–125 mg/dL or HbA1c 5.7%–6.4%, and diabetes = FPG > 125 mg/dL or HbA1c > 6.4%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic syndrome definition used in the exploratory analysis
Registered outcome measures
Weight reduction and its association with morbidity, mortality, and health care spending
“Interventional and epidemiological studies support that reduction of excess body weight reduces morbidity and mortality, and that this reduction is correlated with the magnitude of weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight loss of as little as 5%–10% is associated with a reduction in new onset type 2 diabetes and some cancers and improvements in sleep apnea, hypertension, dyslipidemia, hyperglycemia, osteoarthritis of the knee, and polycystic ovary disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following a 5% reduction of body mass index (BMI), measured as weight in kilograms divided by height in meters squared (kg/m2), adults with a baseline BMI of 30 kg/m2 are estimated to spend 7% less on health care, with the magnitude of benefit correlating to the magnitude of weight reduction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory primary endpoint for weight-reduction drugs
Categorical responder endpoints: regulatory caution
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation
“Sample size of 29 in active and placebo groups was estimated to achieve 84% power to reject the null hypothesis of equal means when the population mean difference (percent change from baseline) between treatment groups is 2.6% with standard deviations (SD) of 3.3% for each treatment group with a significance level (alpha) of 0.05 using a two‐sided, two‐sample t‐test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants randomized and analyzed
“In total, 176 participants were randomized into the study, with approximately 35 participants randomized to placebo or each active treatment group (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety population (N = 175) excludes one participant in the 10 mg group who did not receive treatment and the mITT population used for efficacy analyses (N = 174) excludes that participant and one participant in the placebo group who did not have an evaluable post‐baseline assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Randomized, modified intent-to-treat, and safety populations
“The randomized population includes all participants who were randomized into the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The modified intent‐to‐treat (mITT) population is defined as all participants within the ITT population who had at least one baseline and post‐baseline body weight assessment and received at least one dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety population is defined as all randomized participants who received at least one dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic subset used for the off-treatment follow-up analysis
Mixed model for repeated measures for the primary endpoint
“Percent change from baseline was analyzed using a mixed model for repeated measures (MMRM) approach with baseline treatment, visit, and treatment*visit interaction as factors and baseline weight as a covariate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If there were multiple weights on a particular day, the average of measurements on that day was used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of data after treatment discontinuation and missing data
“Prior to performing the model, any assessments taken after treatment discontinuation +9 days were set to missing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MMRM model used a likelihood‐based approach to manage missing data, assuming data were missing completely at random or missing at random.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity control and supportive analyses
“All tests were two‐sided and conducted at a significance level of 0.05.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A step‐down closed testing procedure was utilized to preserve the family‐wise type I error at 0.05 and each dose group was tested versus placebo in the following order: VK2735 15, 10, 5, and 2.5 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A nonparametric Wilcoxon rank sum test was also used as a supportive analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Logistic regression for categorical weight-reduction endpoints
Exploratory shift analyses: observed values without imputation
Post hoc predicted cardiovascular risk model
Results
Participant disposition
Study completion and reasons for early study discontinuation
“Overall, 167 of the 176 randomized participants (95%) completed the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The reasons for early study discontinuation were AEs (n = 3), withdrawal by participant (n = 3), loss to follow‐up (n = 2), and death (n = 1; Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 24 of 176 participants (14%) discontinued the treatment early (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common reason for early treatment discontinuation was AEs (15/176 participants [8.5%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients could discontinue treatment and remain in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early treatment and study discontinuation by dose arm, safety population
| Measure, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Discontinued treatment early | “5 (14)”View highlighted excerpt for this quote | “2 (6)”View highlighted excerpt for this quote | “4 (11)”View highlighted excerpt for this quote | “5 (14)”View highlighted excerpt for this quote | “7 (20)”View highlighted excerpt for this quote |
| Discontinued study early | “2 (6)”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “2 (6)”View highlighted excerpt for this quote | “2 (6)”View highlighted excerpt for this quote |
Discontinuation as reported in the topline release
Baseline characteristics
Demographic and clinical characteristics by dose arm, randomized population
“Groups were well matched for baseline characteristics in the randomized population (Table 1), with no significant differences between groups for any parameter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of participants were non‐Hispanic, White, and female, and the mean age was approximately 50 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic syndrome at baseline by dose arm
| Arm | MetS at baseline, n/N (%) |
|---|---|
| Placebo | “18/34 (53)” |
| VK2735 2.5 mg | “21/35 (60)” |
| VK2735 5.0 mg | “22/35 (63)” |
| VK2735 10 mg | “14/35 (40)” |
| VK2735 15 mg | “13/35 (37)” |
| All VK2735 | “70/140 (50)” |
Baseline cardiovascular risk factors in the cardiovascular risk analysis subset
| Characteristic | Placebo (n=27) | All VK2735 (n=116) |
|---|---|---|
| Age, years, mean (SD) | “51.9 (12.2)” | “51.8 (12.1)” |
| Class 3 obesity, BMI 40 or higher, n (%) | “13 (48.2)” | “27 (23.3)” |
| Current smoker, n (%) | “2 (7.4)” | “15 (12.9)” |
| Current statin user, n (%) | “5 (18.5)” | “30 (25.9)” |
| Current hypertension medication user, n (%) | “12 (44.4)” | “40 (34.5)” |
Efficacy results
Primary endpoint: percent change in body weight at week 13 by dose, mITT population
“Statistically significant differences in the primary outcome of percent change of weight from baseline to Week 13 were observed for all active treatment groups (−9.1% to −14.7%, vs. −1.7% for placebo) in the mITT population (Table 2, Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results from the Wilcoxon rank sum test were consistent with the primary efficacy analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A dose response was observed for all efficacy measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoint: change in body weight in kilograms at week 13 by dose
| Measure | Placebo (n = 34) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Change from baseline, kg, LS mean (95% CI) | “−1.8 (−3.09, −0.44)”View highlighted excerpt for this quote | “−9.2 (−10.46, −7.86)”View highlighted excerpt for this quote | “−10.7 (−11.97, −9.33)”View highlighted excerpt for this quote | “−13.3 (−14.61, −11.94)”View highlighted excerpt for this quote | “−14.6 (−15.96, −13.30)”View highlighted excerpt for this quote |
| LS mean difference from placebo, kg (95% CI) | Not applicable | “−7.40 (−9.26, −5.54)”View highlighted excerpt for this quote | “−8.88 (−10.76, −7.01)”View highlighted excerpt for this quote | “−11.51 (−13.39, −9.63)”View highlighted excerpt for this quote | “−12.86 (−14.74, −10.99)”View highlighted excerpt for this quote |
Categorical weight reduction of at least 5%, 10%, and 15% at week 13 by dose
“In the active treatment groups, 93% (130/140) of participants had a ≥ 5% weight reduction, compared with 12% (4/34) of participants with placebo treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A dose response was seen at the ≥ 10% weight loss threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The highest two doses (10 and 15 mg) resulted in the largest percentage of patients with a ≥ 15% decrease in body weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Topline release: placebo-adjusted weight change and 10% responders by dose
Weight-loss trajectory: separation from placebo at week 1 and no plateau at week 13
Off-treatment follow-up: weight loss persisting 4 and 7 weeks after the last dose
“In the subset of participants who had post‐dose follow‐up visits, persistent weight loss was seen at 4‐ and 7‐week follow‐up visits (Weeks 16 and 19, respectively), shown in Figure 2B.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics in the follow-up subset
Glycemic status: shift from prediabetes to normoglycemia and change in glucose and HbA1c
“Of the 74 participants who had prediabetes at baseline, 58 (78%) shifted to normoglycemic at Week 13 in the active treatment groups and none shifted from prediabetes to diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic syndrome resolution at week 13, exploratory analysis
| Measure | Placebo | 2.5 mg | 5 mg | 10 mg | 15 mg | Combined VK2735 arms |
|---|---|---|---|---|---|---|
| MetS at baseline, n | “16” | “21” | “21” | “13” | “10” | “65” |
| Shifting to no MetS at week 13, n (%) | “6 (38 %)” | “14 (67 %)” | “14 (67 %)” | “10 (77 %)” | “6 (60 %)” | “44 (68 %)” |
| p value vs placebo | Not applicable | “0.1102” | “0.0217” | “0.0182” | “0.3892” | “0.0244” |
Blood pressure change at week 13 by dose
Lipids and high-sensitivity C-reactive protein at week 13
“Lipid markers generally declined over the 13‐week study in the active treatment group (N = 141).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only total cholesterol had a p value less than 0.05 versus placebo (p = 0.0396) in this time frame.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| hsCRP, mg/L | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Baseline, median | “4.50”View highlighted excerpt for this quote | “3.50”View highlighted excerpt for this quote | “4.00”View highlighted excerpt for this quote | “3.40”View highlighted excerpt for this quote | “3.70”View highlighted excerpt for this quote |
| Change from baseline, median | “0.20”View highlighted excerpt for this quote | “0.10”View highlighted excerpt for this quote | “−0.30”View highlighted excerpt for this quote | “−0.10”View highlighted excerpt for this quote | “−0.75”View highlighted excerpt for this quote |
Lipids and other cardiometabolic parameters, combined VK2735 arms versus placebo
| Parameter | Mean difference, VK2735 compared with placebo | Standardized mean difference (95% CI) |
|---|---|---|
| Total cholesterol, mg/dL | “–8.03” | “–0.26 (–0.75, 0.22)” |
| Triglycerides, mg/dL | “–11.90” | “–0.22 (–0.70, 0.27)” |
| LDL, mg/dL | “–3.98” | “–0.14 (–0.63, 0.34)” |
| HbA1c, % | “–0.32” | “–1.49 (–2.01, –0.97)” |
| BMI, kg/m² | “–3.52” | “–2.32 (–2.90, –1.75)” |
| SBP, mmHg | “–2.40” | “–0.20 (–0.69, 0.28)” |
Predicted 10-year cardiovascular risk at week 13, post hoc analysis
| Predicted 10-year risk | LS mean difference in percent change from baseline, VK2735 vs placebo (95% CI) | P value |
|---|---|---|
| Cardiovascular disease | “–4.14 (–17.22, 8.94)” | “.532” |
| Atherosclerotic cardiovascular disease | “–6.67 (–19.44, 6.09)” | “.303” |
| Heart failure | “–16.21 (–27.37, –5.06)” | “.005” |
BMI category shifts from baseline to week 13, exploratory analysis
| Baseline category and transition | VK2735 combined | Placebo |
|---|---|---|
| Class III obesity at baseline, n | “n=35” | “n=15” |
| Class III, transitioning to Class II | “57 %” | “13 %” |
| Class III, transitioning to Class I | “11 %” | “0 %” |
| Class III, no change in obesity class | “31 %” | “87 %” |
| Class II obesity at baseline, n | “n=51” | “n=10” |
| Class II, transitioning to Class I | “80 %” | “20 %” |
| Class II, transitioning to overweight | “2 %” | “0 %” |
| Class II, no change in obesity class | “18 %” | “80 %” |
| Class I obesity at baseline, n | “n=46” | “n=8” |
| Class I, transitioning to overweight | “65 %” | “12 %” |
| Class I, transitioning to normal weight | “9 %” | “0 %” |
| Class I, no change in obesity class | “26 %” | “75%” |
| Overweight at baseline, n | “n=8” | “n=1” |
| Overweight, transitioning to normal weight | “50 %” | “0 %” |
Cardiometabolic markers by BMI category change among VK2735-treated participants
| Marker, mean (SD) | Baseline (N=124) | Change with at least one BMI category improvement (N=89) | Change with no BMI category change (N=35) |
|---|---|---|---|
| Hemoglobin A1C, % | “5.49 (0.36)” | “-0.34 (0.25)” | “-0.25 (0.17)” |
| Glucose, mg/dL | “99.8 (8.77)” | “-12.4 (9.69)” | “-10.1 (8.56)” |
| Triglycerides, mg/dL | “122.1 (62.16)” | “-20.1 (56.76)” | “-2.2 (52.40)” |
| Waist circumference, cm | “112.7 (11.34)” | “-10.1 (5.90)” | “-7.7 (4.24)” |
| Systolic blood pressure, mmHg | “124.5 (14.53)” | “-9.0 (12.26)” | “-6.0 (13.47)” |
| Diastolic blood pressure, mmHg | “80.1 (8.69)” | “-4.2 (8.27)” | “-2.8 (8.97)” |
| LDL cholesterol, mg/dL | “116.7 (33.12)” | “-12.3 (27.61)” | “-6.9 (23.45)” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Overall treatment-emergent adverse events and severity
“Of the 175 participants in the safety population, 142 (81.1%) experienced at least one TEAE of any type, and 120 of 175 (68.6%) experienced a total of 356 drug‐related TEAEs (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most drug‐related TEAEs were mild or moderate; 71 of 175 participants (40.6%) experienced a maximum severity of grade 1 (mild), 41 (23.4%) grade 2 (moderate), 8 (4.6%) grade 3 (severe), and no participants experienced grade 4 (life‐threatening) AEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common study drug‐related TEAEs were nausea (64/175 participants [36.6%]), constipation (37/175 [21.1%]), and vomiting (22/175 [12.6%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation due to adverse events by dose
“In total, 16 of 175 participants (9.1%) experienced at least one TEAE leading to withdrawal of the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs experienced by these participants were nausea (five participants), vomiting (four participants), diarrhea (two participants), and headache (two participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No other AEs were experienced by more than one participant who discontinued treatment due to TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Event, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| TEAE leading to treatment discontinuation | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “4 (11)”View highlighted excerpt for this quote | “4 (11)”View highlighted excerpt for this quote | “7 (20)”View highlighted excerpt for this quote |
| TEAE leading to study discontinuation | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote |
| Drug-related TEAE leading to study discontinuation | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote |
Gastrointestinal adverse events by dose, all causality
Drug-related gastrointestinal adverse events by severity and dose
“The majority of GI‐related TEAEs were mild or moderate in severity and no grade 4 or 5 TEAEs were observed (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nausea was the most common GI TEAE and had the highest severity (Tables 3 and 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time course of gastrointestinal adverse events
“GI AEs were generally observed early in the study and subsided over time (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dose‐dependent increase in GI TEAEs was observed after initial dosing (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given that the 5 mg dose had a higher GI TEAE rate than the 10 mg dose, there does not seem to be a dose‐dependent increase in GI TEAEs if a 2.5 mg starting dose is used at the beginning of the titration phase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Topline release summary of gastrointestinal tolerability
Serious adverse events and death
“A total of 8 of 175 participants (4.6%) experienced a total of 12 TESAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ten of the twelve TESAEs were considered unrelated to the study drug by investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant in the 5.0 mg dose group experienced two drug‐related TESAEs, atrial fibrillation (possibly related) and dehydration (probably related), which led to study discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One (0.6%) participant died during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“head trauma from a fall” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with underlying causes of hypertension and hyperlipidemia, and it was assessed as not related to the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events of special interest: pancreatitis, gallbladder events, and injection site reactions
“A total of 27 TEAEs of special interest, injection site reaction being the most common, were experienced by 21 of 175 participants (12.0%; Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gallbladder associated AEs of special interest were cholecystitis and cholelithiasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Event of special interest, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Pancreatitis | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Gallbladder associated events | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote |
| Injection site reactions | “3 (9)”View highlighted excerpt for this quote | “2 (6)”View highlighted excerpt for this quote | “5 (14)”View highlighted excerpt for this quote | “5 (14)”View highlighted excerpt for this quote | “4 (11)”View highlighted excerpt for this quote |
Anti-drug antibodies at week 13
“At Week 13, anti‐drug antibodies were detected in between 9% (2.5 mg group) and 23% (10 mg group) of participants in any treatment group (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Measure | 2.5 mg | 5.0 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Anti-VK2735 antibody positive at week 13, n/N (%) | “3/34 (9)”View highlighted excerpt for this quote | “4/34 (12)”View highlighted excerpt for this quote | “8/35 (23)”View highlighted excerpt for this quote | “5/32 (16)”View highlighted excerpt for this quote |
Heart rate change at week 13 by dose
| Heart rate, bpm | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Baseline, mean (SD) | “74.2 (11.01)”View highlighted excerpt for this quote | “69.9 (10.46)”View highlighted excerpt for this quote | “70.2 (10.45)”View highlighted excerpt for this quote | “71.7 (8.53)”View highlighted excerpt for this quote | “69.3 (9.94)”View highlighted excerpt for this quote |
| Change from baseline, mean (SD) | “1.4 (12.15)”View highlighted excerpt for this quote | “3.3 (11.94)”View highlighted excerpt for this quote | “6.1 (9.33)”View highlighted excerpt for this quote | “9.3 (8.51)”View highlighted excerpt for this quote | “6.9 (8.43)”View highlighted excerpt for this quote |
Heart rate and blood pressure as reported on the 2024 congress poster
| Vital sign | Placebo | 2.5 mg | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|---|
| Heart rate, bpm, baseline | “65.7” | “63.5” | “66.9” | “64.3” | “63.9” |
| Heart rate, bpm, mean change at week 13 | “4.4” | “3.8” | “5.0” | “10.8” | “7.1” |
| Systolic blood pressure, mmHg, mean change at week 13 | “-4.4” | “-7.4” | “-8.8” | “-5.4” | “-9.6” |
| Diastolic blood pressure, mmHg, mean change at week 13 | “-2.2” | “-3.7” | “-5.5” | “-1.5” | “-4.3” |
Other selected adverse events by dose: hypotension, dizziness, fatigue, lipase, and hyperthyroidism
Study limitations
Summary: limitations of the VENTURE evidence
VENTURE was a phase 2 dose-finding trial of 13 weeks of treatment in 176 randomized participants, about 35 per arm, conducted at 20 United States sites. The authors state that it was “limited in size and duration” and “not powered to determine statistical significance for differences between treatment groups for most parameters.” The sample size calculation of 29 participants per arm was based on a two-sample t-test. A 13-week result does not address the FDA draft guidance benchmark, which assesses effectiveness after 1 year of treatment at the maintenance dosage. The topline release reported no weight-loss plateau at week 13, and the authors state that “Maximal therapeutic levels were likely not yet achieved in this limited duration study.”
People with diabetes were excluded, BMI above 50 kg/m2 was excluded, and the randomized population was mostly female and White, with between 65.7% and 82.9% female and between 72.2% and 88.6% White participants per arm. The 15 mg arm started at 5.0 mg while the other arms started at 2.5 mg, and the authors state that the “titration schedule and dosing, will be changed to optimize tolerability in future studies.”
The primary analysis was a mixed model for repeated measures in the modified intent-to-treat population (174 participants), with assessments more than 9 days after treatment discontinuation set to missing and data assumed missing at random. This corresponds to an on-treatment estimand; no treatment-policy analysis that retains off-treatment weights was reported. Off-treatment weight data at weeks 16 and 19 were reported only for a pharmacokinetic subset of 75 participants (63 VK2735, 12 placebo). Responder analyses, which the FDA draft guidance states may “inappropriately exaggerate treatment effects”, were secondary endpoints.
Reported figures differ between documents. The topline release reported 23 participants (13%) discontinuing treatment and 10% responder proportions of 4%, 39%, 62%, 70%, and 88%, while the publication reported 24 of 176 (14%) and 3.0%, 40.1%, 65.1%, 70.4%, and 89.1%. Baseline heart rate on the 2024 poster (63.5 to 66.9 bpm) differs from the publication (69.3 to 74.2 bpm), as does the week 13 heart rate change (3.8 to 10.8 bpm versus 3.3 to 9.3 bpm in active arms). Mean heart rate increased by up to 9.3 bpm in the 10 mg arm versus 1.4 bpm with placebo in the publication. Treatment discontinuation due to adverse events rose with dose, from 1 of 35 (3%) at 2.5 mg to 7 of 35 (20%) at 15 mg, with none on placebo.
The metabolic syndrome, BMI category, and predicted cardiovascular risk analyses were exploratory or post hoc, reported in company releases and congress posters without peer review, used observed values without imputation, and reported no adjustment for multiplicity. The cardiovascular risk subset comprised 143 participants, of whom 110 (20 placebo, 90 VK2735) entered the risk model, and all authors of that poster are company employees. No health-related quality of life or patient-reported outcome was reported. The trial was funded by Viking Therapeutics, and every author of the publication was a site investigator or a company employee. No results are posted on ClinicalTrials.gov.